Abstract
Hepatocellular carcinoma is one of the most prevalent forms of cancer throughout the globe. Despite this, therapy of HCC continues to be challenging because of the drawbacks of current treatments options. Lately, nanoparticulate based drug delivery systems have been employed for treatment of variety of cancers, including primary hepatic cancer. These nanocarriers can be tailored to meet the desired requirements on the basis of their size, charge, composition and surface properties. Following attachment to a targeting ligand, the deleterious and toxic effects associated with the drug could be reduced to a minimum, along with site selective delivery of antineoplastic agents. This article attempts to present a review of various nanoparticulate delivery systems which have been explored for the remedy of hepatocellular carcinoma.
Keywords: Asialoglycoprotein receptors, dendrimers, hepatocellular carcinoma, inorganic nanoparticles, Liposomes, magnetic nanoparticles, polymeric nanoparticles, solid lipid nanoparticles.
Current Cancer Therapy Reviews
Title:Nanoparticulate Drug Delivery Systems for Treatment of Hepatocellular Carcinoma
Volume: 10 Issue: 1
Author(s): Shruti S. Shrikhande, Darshana S. Jain, Rajani B. Athawale and Amrita N. Bajaj
Affiliation:
Keywords: Asialoglycoprotein receptors, dendrimers, hepatocellular carcinoma, inorganic nanoparticles, Liposomes, magnetic nanoparticles, polymeric nanoparticles, solid lipid nanoparticles.
Abstract: Hepatocellular carcinoma is one of the most prevalent forms of cancer throughout the globe. Despite this, therapy of HCC continues to be challenging because of the drawbacks of current treatments options. Lately, nanoparticulate based drug delivery systems have been employed for treatment of variety of cancers, including primary hepatic cancer. These nanocarriers can be tailored to meet the desired requirements on the basis of their size, charge, composition and surface properties. Following attachment to a targeting ligand, the deleterious and toxic effects associated with the drug could be reduced to a minimum, along with site selective delivery of antineoplastic agents. This article attempts to present a review of various nanoparticulate delivery systems which have been explored for the remedy of hepatocellular carcinoma.
Export Options
About this article
Cite this article as:
Shrikhande S. Shruti, Jain S. Darshana, Athawale B. Rajani and Bajaj N. Amrita, Nanoparticulate Drug Delivery Systems for Treatment of Hepatocellular Carcinoma, Current Cancer Therapy Reviews 2014; 10 (1) . https://dx.doi.org/10.2174/157339471001140815151936
DOI https://dx.doi.org/10.2174/157339471001140815151936 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Call for Papers in Thematic Issues
Current progress in Protein Degradation and Cancer Therapy
argeted Protein Degradation is gaining momentum in cancer therapy, it facilitate targeting undruggable proteins, it overcome cancer resistance and avoid undesirable side effects. Thus small molecules degraders have emerged as novel therapeutic strategy. Targeted protein degradation (TPD), the process of eliminating a protein of interest hold a great promise for ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Molecular Imaging of Apoptosis In Vivo with Scintigraphic and Optical Biomarkers – A Status Report
Anti-Cancer Agents in Medicinal Chemistry Function of miRNA in Controlling Drug Resistance of Human Cancers
Current Drug Targets Cucurbitacin IIb from Ibervillea sonorae Induces Apoptosis and Cell Cycle Arrest via STAT3 Inhibition
Anti-Cancer Agents in Medicinal Chemistry Glioblastoma Multiforme Formation and EMT: Role of FoxM1 Transcription Factor
Current Pharmaceutical Design CDK Inhibitors: From the Bench to Clinical Trials
Current Drug Targets Current Evidence and Potential Mechanisms of Therapeutic Action of PEDF in Cervical Cancer Treatment
Current Molecular Medicine Recent Developments in the Chemical Biology of Epothilones
Current Pharmaceutical Design Synthesis and Evaluation of a New Series of Arylidene Indanones as Potential Anticancer Agents
Anti-Cancer Agents in Medicinal Chemistry Prevention and Treatment of Regimen-Related Mucosal Toxicity
Recent Patents on Anti-Cancer Drug Discovery The Ambivalent Role of Apoptosis in Experimental Autoimmune Encephalomyelitis and Multiple Sclerosis
Current Pharmaceutical Design Anti-Egfr Therapy in Colorectal Cancer: How to Choose The Right Patient
Current Drug Targets Biosynthetic and Metabolic Alterations in Cancer Growth
Current Angiogenesis (Discontinued) Design, Synthesis and Biological Evaluation of Novel Triazolothiadiazoles Derived from NSAIDs as Anticancer Agents
Anti-Cancer Agents in Medicinal Chemistry AAV as An Immunogen
Current Gene Therapy Editorial [Hot topic: A Dawn of New Era of Signal Transduction in Radiation Oncology (Guest Editor: Yuzuru Niibe)]
Current Signal Transduction Therapy Glycans in Magnetic Resonance Imaging: Determinants of Relaxivity to Smart Agents, and Potential Applications in Biomedicine
Current Medicinal Chemistry Review on Documented Medicinal Plants used for the Treatment of Cancer
Current Traditional Medicine Pyrimidine Nucleosides in Molecular PET Imaging of Tumor Proliferation
Current Medicinal Chemistry Trabectedin as a New Chemotherapy Option in the Treatment of Relapsed Platinum Sensitive Ovarian Cancer
Current Pharmaceutical Design A Systematic Review of Selected Musculoskeletal Late Effects in Survivors of Childhood Cancer
Current Pediatric Reviews